Market Intelligence, Clinical Progress, and High-Purity Reagents for Solid Tumor Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CDCP1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CDCP1 ECD-Fc Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed for native glycosylation. |
View CDCP1 Products |
| Gene Delivery | CDCP1 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and conformation-dependent screening. |
View CDCP1 Products |
| Benchmark Ab | Anti-CDCP1 Recombinant Antibody (Sequence of Praluzatamab) Recombinant positive control for binding and internalization assays. |
View CDCP1 Products |
| Validator | CDCP1 siRNA Set For target knockdown validation and assay specificity controls. |
View CDCP1 Products |
| Related Target A | EGFR Synergistic oncogenic signaling partner; co-expression modulates CDCP1 phosphorylation and downstream invasion. |
View EGFR Products |
| Related Target B | CD3E T-cell recruitment partner for bispecific antibody (BsAb) developments targeting solid tumors. |
View CD3E Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species Cyno/Mouse Evaluation | Human, Mouse, and Cynomolgus CDCP1 ortholog proteins available with >95% purity to ensure robust cross-reactivity profiling. |
| Native Glycosylation Preservation | HEK293 expression system guarantees correct post-translational modifications, crucial for clinical-mimic antibody binding. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies (biosimilars) included for assay calibration. |
| False Positives in Knockdown | Sequence-specific validated siRNA pools included for target-specific validation. |
Live CDCP1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CDCP1 therapeutics is intensifying, with major players shifting focus from traditional mAbs to antibody-drug conjugates (ADCs), probody-drug conjugates (PDCs), and radioligand therapies (RLT). As first-generation therapies reach the clinic, the next wave of R&D is targeting tumor-specific cleavage mechanisms and bispecific T-cell engager strategies to bypass normal tissue toxicity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Probody-Drug Conjugate (PDC) | CytomX Therapeutics | Breast Cancer, Head and Neck Cancer | Protease-cleavable assay validation (Requires ultra-pure CDCP1 ECD-Fc) |
| Radioligand Therapy (RLT) | Academic Medical Centers, Convergent Therapeutics | Prostate Cancer, Pancreatic Cancer | High-affinity internalization screening (Requires HEK293-expressed CDCP1) |
| Bispecific Antibody / T-Cell Engager | Amgen, Macrogenics | Solid Tumors | Dual-binding affinity validation (Requires CDCP1 and CD3E target panels) |